Roth MKM analyst Boobalan Pachaiyappan initiated coverage of Gain Therapeutics (GANX) with a Buy rating and $7 price target Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on GANX: Gain Therapeutics Advances Parkinson’s Therapy Development Closing Bell Movers: Applied Materials down 6% after earnings, guidance Gain Therapeutics reports Q3 EPS (17c), consensus (21c) Is GANX a Buy, Before Earnings? Gain Therapeutics presents data at 36th ENA symposium